Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results

作者
Alexander Starodub,Allyson J. Ocean,Aditya Bardia,Michael J. Guarino,Wells A. Messersmith,Jordan D. Berlin,Vincent J. Picozzi,Sajeve Samuel Thomas,Gregory A. Masters,Linda T. Vahdat,Ingrid A. Mayer,Rebecca Moroose,Jennifer Robinson Diamond,Scott T. Tagawa,Manish A. Shah,Francois E. Wilhelm,William A. Wegener,Pius P. Maliakal,Robert M. Sharkey,David M. Goldenberg
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:75 (15_Supplement): CT236-CT236 被引量:4
标识
DOI:10.1158/1538-7445.am2015-ct236
摘要

Abstract Background: Sacituzumab govitecan (IMMU-132) is a new ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, camptothecin (irinotecan), conjugated to an anti-Trop-2 antibody. In vitro and in vivo preclinical data suggest that IMMU-132 is a unique ADC, being most efficacious at a high drug-antibody ratio (DAR) of 7.6, and capable of delivering up to 135-fold more SN-38 than its parental drug, irinotecan, in a human cancer xenograft. In vitro studies also demonstrate specific double-stranded DNA breaks by the internalizing ADC. Methods: IMMU-132 is completing a phase I/II clinical trial with phase II expansion after MTD determination (ClinicalTrials.gov.NCT01631552) in patients with advanced cancers that typically express high levels of Trop-2, at doses of 8 and 10 mg/kg on days 1 and 8 of 21-day repeated cycles. Efficacy (N = 91) and safety (N = 130) results are provided. Results: The% of grades 3/4 AEs for both dose levels are neutropenia (16/4), febrile neutropenia (4/4), anemia (4/0), diarrhea (4/0), and fatigue (4/0) (Table 1). No patient discontinued therapy due to toxicity, and no patient showed immunogenicity despite repeated therapy. Patient dose reductions were 15-16%, and dose delays after first 2 cycles were 3-4%. Conclusions: IMMU-132 shows activity in patients with diverse cancers, even when they no longer responded to a topoisomerase inhibitor. It appears to have a manageable toxicity profile, with promising efficacy at a high therapeutic index in patients with heavily-pretreated metastatic cancers, especially TNBC, SCLC, and NSCLC. Based on these results, this ADC carrying a moderately-toxic drug that is the active metabolite of a currently-used camptothecin analogue represents a novel cancer therapeutic that challenges the current dogma of requiring ultratoxic drugs conjugated at low DARs for ADC therapy. Tumor typeORR (CR+PR)Disease stabilization (CR+PR+SD)Clinical benefit (CR+PR+ SD > 6 moMedian TPP (mo)TNBC (N = 31)TNBC (N = 31)23%71%39%3.7+NSCLC (N = 15)27%73%42%3.3+SCLC (N = 19)26%53%29%2.8+CRC (N = 26)4%58%24%3.7 Citation Format: Alexander N. Starodub, Allyson J. Ocean, Aditya Bardia, Michael J. Guarino, Wells Messersmith, Jordan Berlin, Vincent J. Picozzi, Sajeve S. Thomas, Gregory Masters, Linda T. Vahdat, Ingrid A. Mayer, Rebecca Moroose, Jennifer S. Diamond, Scott T. Tagawa, Manish A. Shah, Francois Wilhelm, William A. Wegener, Pius Maliakal, Robert M. Sharkey, David M. Goldenberg. Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT236. doi:10.1158/1538-7445.AM2015-CT236

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蘑菇的应助被Dingwang采纳,获得10
刚刚
朴素的虔完成签到 ,获得积分10
刚刚
强健的寒松完成签到,获得积分10
1秒前
1秒前
小鱼爱吃肉的应助被yan采纳,获得10
1秒前
1秒前
番茄大王完成签到,获得积分10
2秒前
3秒前
江小雪发布了新的文献求助10
3秒前
谨慎甜瓜完成签到,获得积分10
3秒前
阿迪完成签到 ,获得积分10
3秒前
YY的应助被zzzxxyy采纳,获得30
3秒前
战魂发布了新的文献求助10
3秒前
富贵儿完成签到,获得积分10
4秒前
泷飞风舞2025完成签到,获得积分10
4秒前
deny完成签到,获得积分10
4秒前
十一完成签到 ,获得积分10
4秒前
小巧紫蓝完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
Fan宝儿发布了新的文献求助10
5秒前
5秒前
跳跃芷蕊完成签到,获得积分10
5秒前
无花果的应助被Hao采纳,获得10
5秒前
祝我能顺利毕业完成签到,获得积分10
5秒前
羡鱼完成签到 ,获得积分10
5秒前
胡德完成签到 ,获得积分10
5秒前
四季豆完成签到,获得积分10
5秒前
dao完成签到,获得积分10
5秒前
天空之城完成签到,获得积分10
5秒前
chaser完成签到,获得积分10
5秒前
5秒前
cccui完成签到,获得积分10
5秒前
初景的应助被鱼鱼和石头采纳,获得20
6秒前
难过的安双完成签到,获得积分10
6秒前
6秒前
Ius完成签到,获得积分10
6秒前
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159929
求助须知:如何正确求助?哪些是违规求助? 9555266
关于积分的说明 21726335
捐赠科研通 7749807
什么是DOI,文献DOI怎么找? 3427310
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471654